Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, September 30, 2022.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2022 (2022-09-30): -448.71%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-208.64%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Foghorn Therapeutics Inc.
Market Cap
$115.67M
Return on Equity (ROE)
N/A
TTM Avg
-208.64%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.76M
Return on Equity (ROE)
-22.45%
TTM Avg
-22.96%
3Y Avg
-17.88%
5Y Avg
-19.06%
Market Cap
$114.46M
Return on Equity (ROE)
-478.26%
TTM Avg
-687.50%
3Y Avg
165.05%
5Y Avg
111.70%
Market Cap
$113.89M
Return on Equity (ROE)
-209.73%
TTM Avg
-196.07%
3Y Avg
-130.72%
5Y Avg
-67.26%
Market Cap
$113.77M
Return on Equity (ROE)
-0.05%
TTM Avg
-43.47%
3Y Avg
9.13%
5Y Avg
-18.50%
Market Cap
$117.76M
Return on Equity (ROE)
-61.33%
TTM Avg
-137.84%
3Y Avg
-101.43%
5Y Avg
-77.25%
Market Cap
$112.94M
Return on Equity (ROE)
-66.12%
TTM Avg
-291.11%
3Y Avg
1023.70%
5Y Avg
687.99%
Market Cap
$118.59M
Return on Equity (ROE)
-148.56%
TTM Avg
-96.59%
3Y Avg
-83.25%
5Y Avg
-64.44%
Market Cap
$112.57M
Return on Equity (ROE)
-105.40%
TTM Avg
-90.09%
3Y Avg
-60.23%
5Y Avg
-18.64%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $115.67M | N/A | -208.64% | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | -22.45% | -22.96% | -17.88% | -19.06% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | -478.26% | -687.50% | 165.05% | 111.70% |
| Genelux Corporation (GNLX)vs › | $113.89M | -209.73% | -196.07% | -130.72% | -67.26% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -0.05% | -43.47% | 9.13% | -18.50% |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | -61.33% | -137.84% | -101.43% | -77.25% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | -66.12% | -291.11% | 1023.70% | 687.99% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | -148.56% | -96.59% | -83.25% | -64.44% |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | -105.40% | -90.09% | -60.23% | -18.64% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | -57.47% | -26.63% | 16.73% | 210.40% |
ROE
N/A
ROA
-31.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2022-09-30 | -448.71% |
| 2022-06-30 | -229.78% |
| 2022-03-31 | -145.37% |
| 2021-12-31 | -104.59% |
| 2021-09-30 | -114.76% |
| 2021-06-30 | -81.79% |
| 2021-03-31 | -62.19% |
| 2020-12-31 | -47.06% |
| 2020-06-30 | -320.54% |
